Freeline Therapeutics Holdings plc
FRLNNASDAQHealthcare
$6.49
+$0.01(+0.15%)
Market Cap$28283096
P/E Ratio—
52W High$8.745
52W Low$2.11
Freeline Therapeutics Holdings plc (FRLN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FRLN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: Apr 2, 2024EPS Actual
-$5.22
Est. -$0.26 · -1907.7%
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
Apr 2, 2024
After Market Close
▼ Miss EPS
FRLN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | Apr 2, 2024 | -$0.26 | -$5.22 | -1907.7% | — | — | — |
| ▲ Q4 FY2023 | Dec 1, 2023 | -$0.23 | -$0.18 | +21.7% | $0.00B | — | — |
| ▲ Q3 FY2023 | Aug 15, 2023 | -$3.62 | -$0.21 | +94.2% | $0.00B | — | — |
| ▼ Q2 FY2023 | Apr 4, 2023 | -$3.10 | -$5.22 | -68.4% | — | — | — |
| ▼ Q1 FY2023 | Mar 30, 2023 | -$0.29 | -$0.97 | -234.5% | — | — | — |
| ▲ Q4 FY2022 | Nov 15, 2022 | -$6.42 | -$2.99 | +53.4% | — | — | — |
| ▲ Q3 FY2022 | Aug 9, 2022 | -$8.06 | -$4.78 | +40.7% | — | — | — |
| ▼ Q2 FY2022 | May 10, 2022 | -$8.66 | -$9.40 | -8.6% | — | — | — |
Q2 FY2024
Apr 2, 2024Miss
EPS Actual
-$5.22
EPS Est.
-$0.26
EPS Surpr.
-1907.7%
Revenue
—
Q4 FY2023
Dec 1, 2023Beat
EPS Actual
-$0.18
EPS Est.
-$0.23
EPS Surpr.
+21.7%
Revenue
$0.00B
Q3 FY2023
Aug 15, 2023Beat
EPS Actual
-$0.21
EPS Est.
-$3.62
EPS Surpr.
+94.2%
Revenue
$0.00B
Q2 FY2023
Apr 4, 2023Miss
EPS Actual
-$5.22
EPS Est.
-$3.10
EPS Surpr.
-68.4%
Revenue
—
Q1 FY2023
Mar 30, 2023Miss
EPS Actual
-$0.97
EPS Est.
-$0.29
EPS Surpr.
-234.5%
Revenue
—
Q4 FY2022
Nov 15, 2022Beat
EPS Actual
-$2.99
EPS Est.
-$6.42
EPS Surpr.
+53.4%
Revenue
—
Q3 FY2022
Aug 9, 2022Beat
EPS Actual
-$4.78
EPS Est.
-$8.06
EPS Surpr.
+40.7%
Revenue
—
Q2 FY2022
May 10, 2022Miss
EPS Actual
-$9.40
EPS Est.
-$8.66
EPS Surpr.
-8.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.63 | $1.54 | $1.43 | 0 |
| Q2 FY2024 | $1.42 | $1.34 | $1.25 | 0 |
| Q1 FY2024 | $1.67 | $1.58 | $1.47 | 1 |
| Q4 FY2023 | $-0.18 | $-0.13 | $-0.07 | 1 |
| Q3 FY2023 | $-0.23 | $-0.20 | $-0.17 | 1 |
| Q2 FY2023 | $-3.83 | $-3.62 | $-3.36 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | Apr 2, 2024 | -1907.7% | $6.48 | — | — |
| ▲ Q4 FY2023 | Dec 1, 2023 | +21.7% | $6.31 | $6.23 | -1.27% |
| ▲ Q3 FY2023 | Aug 15, 2023 | +94.2% | $4.10 | $3.86 | -5.85% |
| ▼ Q2 FY2023 | Apr 4, 2023 | -68.4% | $7.05 | $6.60 | -6.38% |
| ▼ Q1 FY2023 | Mar 30, 2023 | -234.5% | $6.78 | $6.62 | -2.36% |
| ▲ Q4 FY2022 | Nov 15, 2022 | +53.4% | $10.28 | $10.20 | -0.78% |
| ▲ Q3 FY2022 | Aug 9, 2022 | +40.7% | $12.77 | $13.68 | +7.13% |
| ▼ Q2 FY2022 | May 10, 2022 | -8.6% | $11.63 | $10.58 | -9.03% |
Q2 FY2024—
Report Date
Apr 2, 2024
EPS Beat/Miss
-1907.7%
Price Before
$6.48
Price After
—
Q4 FY2023-1.27%
Report Date
Dec 1, 2023
EPS Beat/Miss
+21.7%
Price Before
$6.31
Price After
$6.23
Q3 FY2023-5.85%
Report Date
Aug 15, 2023
EPS Beat/Miss
+94.2%
Price Before
$4.10
Price After
$3.86
Q2 FY2023-6.38%
Report Date
Apr 4, 2023
EPS Beat/Miss
-68.4%
Price Before
$7.05
Price After
$6.60
Q1 FY2023-2.36%
Report Date
Mar 30, 2023
EPS Beat/Miss
-234.5%
Price Before
$6.78
Price After
$6.62
Q4 FY2022-0.78%
Report Date
Nov 15, 2022
EPS Beat/Miss
+53.4%
Price Before
$10.28
Price After
$10.20
Q3 FY2022+7.13%
Report Date
Aug 9, 2022
EPS Beat/Miss
+40.7%
Price Before
$12.77
Price After
$13.68
Q2 FY2022-9.03%
Report Date
May 10, 2022
EPS Beat/Miss
-8.6%
Price Before
$11.63
Price After
$10.58
Avg Beat Reaction-0.19%
Avg Miss Reaction-5.92%
Beat Rate4 / 8 quarters
Largest Move-9.03% (Q2 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FRLN ends December
Freeline Therapeutics Holdings plc (FRLN) most recently reported earnings on April 2, 2024 for Q2 FY2024, posting EPS of $-5.22 — missing the analyst consensus of $-0.26 by -1907.7%. The next FRLN earnings date is expected around September 1, 2026.
Each quarter, investors track FRLN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FRLN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FRLN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FRLN earnings · 5 questionsFreeline Therapeutics Holdings plc's next earnings report is expected around September 1, 2026. FRLN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FRLN historically reports after market close (AMC).
FRLN earnings datewhen is FRLN earningsFRLN next earnings datewhen does FRLN report earningsFRLN earnings calendar
▸ Source: FMP · Freeline Therapeutics Holdings plc SEC filings · US GAAP · Freeline Therapeutics Holdings plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026